Jpmorgan Chase & CO Mirum Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 23,832 shares of MIRM stock, worth $964,004. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,832
Previous 145,560
83.63%
Holding current value
$964,004
Previous $3.66 Million
77.74%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding MIRM
# of Institutions
172Shares Held
54.2MCall Options Held
96.1KPut Options Held
54.8K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.5MShares$263 Million13.09% of portfolio
-
Janus Henderson Group PLC London, X04.99MShares$202 Million0.09% of portfolio
-
Bvf Inc San Francisco, CA4.37MShares$177 Million4.57% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.61MShares$146 Million2.18% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$131 Million0.0% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.49B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...